中金:重申融創(1918.HK)“優於大市”評級 目標價47.9港元
中金髮表報告指,融創中國(1918.HK)首九個月月銷售額按年增長16%,料公司強勁的銷售將帶來明顯的收入增長,重申對公司“優於大市”的投資評級,目標價維持47.9港元不變。
中金相信,融創可輕鬆完成今年5500億元人民幣的銷售目標,並預計其明年銷售增速將在大約20%的水平。該行表示,融創有充足的未開盤銷售和穩定的毛利率,預期今明兩年核心淨利潤分別按年增長31%和25%,至281億和351億元人民幣。
另外,該行預期,融創透過加快銷售速度及減少買地,其今年底的淨負債率有望收窄至140%,較上半年末的224%的水平明顯減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.